胎盘蛋白13在子痫前期发生中的作用及相关药物治疗研究进展  

Research progress on the role of placental protein 13 in the development of preeclampsia and related drug treatment

作　　者：赵丽红 王晨曦 赵英 李洪英 ZHAO Lihong;WANG Chenxi;ZHAO Ying;LI Hongying(Department of Obstetrics,Affiliated Qujing Hospital of Kunming Medical University,Qujing 655000,China)

机构地区：[1]昆明医科大学附属曲靖医院产科,云南曲靖655000

出　　处：《陕西医学杂志》2025年第2期282-284,288,共4页Shaanxi Medical Journal

基　　金：国家自然科学基金资助项目(81660545)。

摘　　要：子痫前期(PE)是导致孕产妇及围生儿病死率和患病率升高的主要原因之一,主要表现为妊娠前血压正常,妊娠20周后发现高血压和蛋白尿。胎盘蛋白13(PP13)是妊娠过程中具有重要作用的蛋白质,由胎盘滋养细胞合成及分泌,参与胎盘种植、维持妊娠,还能调节缩血管/扩血管平衡,影响血管重塑,与PE发生存在一定相关性。PE可导致孕产妇并发心血管疾病、胎儿生长受限、胎儿窘迫等多种不良妊娠结局,随着对PE的不断深入研究,部分药物被证实可用于PE治疗。故现对PP13在PE发生中的作用机制以及相关药物治疗的研究进展进行综述。Preeclampsia(PE)is one of the leading causes of increased maternal and perinatal morbidity and mortality,characterized by normal blood pressure before pregnancy and the onset of hypertension and proteinuria after 20 weeks of gestation.Placental protein 13(PP13)is an important protein in the pregnancy process,synthesized and secreted by placental trophoblast cells,involved in placental implantation,maintenance of pregnancy,regulation of vasoconstriction/vasodilation balance and vascular remodeling,which is associated with the occurrence of PE.PE can lead to various adverse pregnancy outcomes such as cardiovascular diseases in pregnant women,fetal growth restriction and fetal distress.With continuous in-depth research on PE,some drugs have been proven to be effective in the treatment of PE.Therefore,this article reviews the role of PP13 in the pathogenesis of PE and the research progress of related drug treatments.

关 键 词：子痫前期 胎盘蛋白13 发病机制 药物治疗 妊娠结局 

分 类 号：R714.25[医药卫生—妇产科学]